Citius Pharmaceuticals, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended September 30, 2020. This is an annual report, not a standalone fourth-quarter report. Citius is a clinical-stage specialty pharmaceutical company with no approved products or revenue.
Financial performance and liquidity
| Metric | FY2020 / September 30, 2020 | FY2019 / September 30, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $8.81 million | $8.60 million |
| General and administrative expense | $8.09 million | $6.29 million |
| Total operating expenses | $17.71 million | $15.60 million |
| Net loss | $17.55 million | $15.56 million |
| Net cash used in operating activities | $16.93 million | $12.44 million |
| Cash and cash equivalents | $13.86 million | $7.89 million |
| Working capital | $9.88 million | Not clearly stated |
| Total liabilities | $10.10 million | $9.59 million |
| Stockholders’ equity | $33.67 million | $27.15 million |
Gross margin is not meaningful because the company had no revenue. The $1.99 million increase in net loss was primarily driven by higher G&A expense. R&D increased modestly overall: Mino-Lok spending declined to $6.21 million, while Halo-Lido rose to $1.65 million; $846,232 was reported for the proposed cellular therapy program. G&A rose by $1.81 million, including costs associated with a new chief medical officer, consulting, investor relations, legal and advisory services.
Cash increased largely through equity financings and warrant exercises. Financing activities provided $22.90 million, including $164,583 from a Paycheck Protection Program loan. The balance sheet also included $172,970 of related-party notes payable, a $164,583 PPP note and $1.01 million of operating lease liabilities. Management estimated available capital would fund operations through March 2021 and said additional financing would be needed. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern.
Material changes and developments
- Shares outstanding increased from 28.93 million to 55.58 million during the year. At September 30, 2020, a further 26.83 million shares were reserved for warrants and 3.39 million for options, presenting potential dilution.
- The company raised net proceeds through several 2020 offerings and warrant exercises. FY2020 financing cash flow exceeded FY2019’s $11.15 million.
- The 2019 comparative balance sheet was restated for a previously omitted deferred tax liability and related goodwill. At September 30, 2019, the restatement added $4.99 million of deferred tax liabilities and $7.76 million of goodwill, and reduced accumulated deficit by $2.77 million. The filing reports no impact on FY2019 net loss.
- In October 2020, after fiscal year-end, subsidiary NoveCite entered an exclusive license agreement for iPSC-derived mesenchymal stem-cell therapy focused on acute pneumonitis/ARDS, including COVID-19-related ARDS. The agreement included a $5 million upfront payment, a 25% NoveCite interest for the licensor, and up to $51 million in development and regulatory milestones, plus royalties.
Outlook, risks and unusual items
- Mino-Lok: The Phase 3 trial had 29 active enrolling sites as of November 15, 2020. The data monitoring committee recommended continuing without modification and reported no safety signals; this was not a finding of efficacy. A planned 75% interim efficacy analysis was expected by March 2021. COVID-19 disrupted trial operations, and completion was then expected in the second half of 2021.
- Other programs: Management expected FY2021 R&D expense to increase as it continued Mino-Lok, advanced Halo-Lido and Mino-Wrap, and pursued the ARDS program. Halo-Lido Phase 2b was anticipated to begin in the first quarter of 2021. FDA feedback on Mino-Wrap’s preclinical program was described as generally supportive, with additional clinical guidance.
- Funding and development risks: The company has a history of losses, no product revenue, and requires additional capital. Failure to raise funds could force delays, reductions or termination of programs. Clinical outcomes, FDA approval, commercialization, reimbursement and market acceptance remain uncertain.
- COVID-19 and operations: The pandemic affected clinical sites and may delay enrollment, raise costs and impair future access to capital. Citius relies on third parties for clinical research and manufacturing and has no in-house sales or distribution capability.
- Governance and listing: Citius owned 75% of NoveCite; overlapping directors and officers and the chairman’s relationship with Novellus create potential conflicts. The company regained Nasdaq’s minimum-bid-price compliance in July 2020 after prior noncompliance.
- Unusual financial items: FY2020 included $110,207 of other income from an FDA fee refund. The company reported no material litigation and no off-balance-sheet arrangements. The financial statements were prepared on a going-concern basis.
Important facts for investors to verify
- Current cash runway and subsequent financing after the stated March 2021 estimate, including the terms and dilution from any capital raises.
- Mino-Lok enrollment, interim-analysis results, COVID-related timing changes and the eventual Phase 3 readout.
- Whether Halo-Lido and Mino-Wrap milestones and planned development timelines were achieved, and the regulatory pathway and data requirements for each.
- NoveCite’s actual funding needs, ownership dilution, license obligations and progress toward IND-enabling work and clinical development.
- Outstanding warrants and options, fully diluted share count, and the effect of potential exercises or future equity issuance.
- The assumptions behind the going-concern assessment and the restated 2019 financial statements, including the deferred tax liability and goodwill treatment.